Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Jianjiao Ni, Guodong Li, Xi Yang, Li Chu, Jialei Wang, Yida Li, Liqing Zou, Yuan Li, Congying Xie, Zhengfei Zhu

ABSTRACT

BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown. METHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2. RESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p = 0.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p = 0.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p = 0.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p = 0.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p = 0.048). CONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions. More... »

PAGES

44

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1

DOI

http://dx.doi.org/10.1186/s13014-019-1240-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112739159

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30866974


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ni", 
        "givenName": "Jianjiao", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Guodong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "Xi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chu", 
        "givenName": "Li", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Jialei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Yida", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zou", 
        "givenName": "Liqing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Yuan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Affiliated Hospital of Wenzhou Medical University", 
          "id": "https://www.grid.ac/institutes/grid.414906.e", 
          "name": [
            "Radiotherapy and Chemotherapy Department, the 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xie", 
        "givenName": "Congying", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Zhengfei", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jama.2016.9839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003526472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1408440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005474865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-12-0868", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007331796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2014.12.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008009645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.59.0539", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016158843"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semcdb.2016.09.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016585125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt572", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016737978"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2013.11.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019077778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3111/13696998.2014.1003644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027632484"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0000000000000648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029331288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1006448", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029333869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035605294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.prro.2016.05.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038999889"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.3312", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040085264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/02841860802662722", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040375196"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.62.0138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042043060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.radonc.2014.12.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043860460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1214886", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046181766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3182745948", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047119041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep07268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047997157", 
          "https://doi.org/10.1038/srep07268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmct0806951", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050338991"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(17)30123-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074187710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079320625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.71.5904", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085191926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30339-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085964284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2017.395", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092730269", 
          "https://doi.org/10.1038/bjc.2017.395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2017.12.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099711099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2017.12.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099711099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103369506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3389/fonc.2018.00154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103883556"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7150/jca.24950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103988345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.77.5841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104022577"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21492", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106916204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy405", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106933161"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown.\nMETHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2.\nRESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p\u2009=\u20090.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p\u2009=\u20090.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p\u2009=\u20090.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p\u2009=\u20090.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p\u2009=\u20090.048).\nCONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13014-019-1240-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1036451", 
        "issn": [
          "1748-717X"
        ], 
        "name": "Radiation Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses", 
    "pagination": "44", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b71775b5bfb19f6595306d6380c59c9381c201c46e861e0ef9b464d000d670b7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30866974"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101265111"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13014-019-1240-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112739159"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13014-019-1240-1", 
      "https://app.dimensions.ai/details/publication/pub.1112739159"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78970_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13014-019-1240-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'


 

This table displays all metadata directly associated to this object as RDF triples.

229 TRIPLES      21 PREDICATES      62 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13014-019-1240-1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Ne5d6e4296b764161af45cf304616ae2b
4 schema:citation sg:pub.10.1038/bjc.2017.395
5 sg:pub.10.1038/srep07268
6 https://doi.org/10.1001/jama.2016.9839
7 https://doi.org/10.1016/j.ijrobp.2013.11.010
8 https://doi.org/10.1016/j.ijrobp.2014.12.010
9 https://doi.org/10.1016/j.jtho.2017.12.006
10 https://doi.org/10.1016/j.prro.2016.05.004
11 https://doi.org/10.1016/j.radonc.2014.12.009
12 https://doi.org/10.1016/j.semcdb.2016.09.016
13 https://doi.org/10.1016/s0140-6736(17)30123-x
14 https://doi.org/10.1016/s1470-2045(17)30339-x
15 https://doi.org/10.1056/nejmct0806951
16 https://doi.org/10.1056/nejmoa1006448
17 https://doi.org/10.1056/nejmoa1214886
18 https://doi.org/10.1056/nejmoa1408440
19 https://doi.org/10.1080/02841860802662722
20 https://doi.org/10.1093/annonc/mds124
21 https://doi.org/10.1093/annonc/mdt572
22 https://doi.org/10.1093/annonc/mdw305
23 https://doi.org/10.1093/annonc/mdy121
24 https://doi.org/10.1093/annonc/mdy405
25 https://doi.org/10.1097/jto.0000000000000648
26 https://doi.org/10.1097/jto.0b013e3182745948
27 https://doi.org/10.1158/1535-7163.mct-12-0868
28 https://doi.org/10.1200/jco.2007.15.3312
29 https://doi.org/10.1200/jco.2014.59.0539
30 https://doi.org/10.1200/jco.2015.62.0138
31 https://doi.org/10.1200/jco.2016.71.5904
32 https://doi.org/10.1200/jco.2017.77.5841
33 https://doi.org/10.3111/13696998.2014.1003644
34 https://doi.org/10.3322/caac.21492
35 https://doi.org/10.3389/fonc.2018.00154
36 https://doi.org/10.7150/jca.24950
37 schema:datePublished 2019-12
38 schema:datePublishedReg 2019-12-01
39 schema:description BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown. METHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2. RESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p = 0.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p = 0.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p = 0.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p = 0.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p = 0.048). CONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree true
43 schema:isPartOf N29281dcaf08946cb94319cef195186ea
44 N9ab18edca8d84532873616f0f531bf93
45 sg:journal.1036451
46 schema:name Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses
47 schema:pagination 44
48 schema:productId N684fee5fefc64419bc36a551cca568da
49 N8547b0304c214fada96a4d050863307f
50 Nba521bbe6e5e4bdf844e84861a54a430
51 Ncc5339b594414ee98a72832d641a4326
52 Nf9f8b8a2402644de989dc075202dd073
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112739159
54 https://doi.org/10.1186/s13014-019-1240-1
55 schema:sdDatePublished 2019-04-11T13:20
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher N86801a1732fa43e6856959d5d74e0f67
58 schema:url https://link.springer.com/10.1186%2Fs13014-019-1240-1
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N047ca003f52d4626aad01a1831fe90d7 rdf:first Ne89ddb2a20be48fea7f0865782076770
63 rdf:rest N66e621798b224aa2b41e54def37c2352
64 N10ce7be65bcc4f52a05f081f39f5a022 rdf:first N6f88f877734f474795139818370ab614
65 rdf:rest rdf:nil
66 N25f9645c50864d4c9ed1da128c203587 schema:affiliation https://www.grid.ac/institutes/grid.414906.e
67 schema:familyName Xie
68 schema:givenName Congying
69 rdf:type schema:Person
70 N278fc8ad10ba4cba9b19d464309be480 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
71 schema:familyName Li
72 schema:givenName Yida
73 rdf:type schema:Person
74 N29281dcaf08946cb94319cef195186ea schema:issueNumber 1
75 rdf:type schema:PublicationIssue
76 N66e621798b224aa2b41e54def37c2352 rdf:first Ne0666471a5674d838db6f84285ab6e3d
77 rdf:rest N9ae8f6de3bb64e88b7e7bd72992dd1ba
78 N684fee5fefc64419bc36a551cca568da schema:name pubmed_id
79 schema:value 30866974
80 rdf:type schema:PropertyValue
81 N6f88f877734f474795139818370ab614 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
82 schema:familyName Zhu
83 schema:givenName Zhengfei
84 rdf:type schema:Person
85 N8547b0304c214fada96a4d050863307f schema:name readcube_id
86 schema:value b71775b5bfb19f6595306d6380c59c9381c201c46e861e0ef9b464d000d670b7
87 rdf:type schema:PropertyValue
88 N86801a1732fa43e6856959d5d74e0f67 schema:name Springer Nature - SN SciGraph project
89 rdf:type schema:Organization
90 N8952015b1bc24e2685311188c7efd9f4 rdf:first N98953cdfb6bc4772b965762cf54c3a22
91 rdf:rest Nbd3e93ac92004e5a970e543a31c2caed
92 N98953cdfb6bc4772b965762cf54c3a22 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
93 schema:familyName Li
94 schema:givenName Yuan
95 rdf:type schema:Person
96 N9ab18edca8d84532873616f0f531bf93 schema:volumeNumber 14
97 rdf:type schema:PublicationVolume
98 N9ae8f6de3bb64e88b7e7bd72992dd1ba rdf:first Ne2a600c2d332441caad767577c1d39b6
99 rdf:rest Ncf44c43aaf39475ab060c6bfbc81066c
100 Naa40a14bc1c64f69986adbc84c162f9b schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
101 schema:familyName Ni
102 schema:givenName Jianjiao
103 rdf:type schema:Person
104 Nba521bbe6e5e4bdf844e84861a54a430 schema:name doi
105 schema:value 10.1186/s13014-019-1240-1
106 rdf:type schema:PropertyValue
107 Nbd3e93ac92004e5a970e543a31c2caed rdf:first N25f9645c50864d4c9ed1da128c203587
108 rdf:rest N10ce7be65bcc4f52a05f081f39f5a022
109 Ncc5339b594414ee98a72832d641a4326 schema:name dimensions_id
110 schema:value pub.1112739159
111 rdf:type schema:PropertyValue
112 Ncf0746f9935a418988d5337f704ba2f1 rdf:first N278fc8ad10ba4cba9b19d464309be480
113 rdf:rest Ndd8a95500f2e4a5bb0f36772374bb280
114 Ncf44c43aaf39475ab060c6bfbc81066c rdf:first Ned93324152f24f9eb514859c2014eaae
115 rdf:rest Ncf0746f9935a418988d5337f704ba2f1
116 Ndd8a95500f2e4a5bb0f36772374bb280 rdf:first Nf2e50e9b33d9487eb55d54c54ab6ca84
117 rdf:rest N8952015b1bc24e2685311188c7efd9f4
118 Ne0666471a5674d838db6f84285ab6e3d schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
119 schema:familyName Yang
120 schema:givenName Xi
121 rdf:type schema:Person
122 Ne2a600c2d332441caad767577c1d39b6 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
123 schema:familyName Chu
124 schema:givenName Li
125 rdf:type schema:Person
126 Ne5d6e4296b764161af45cf304616ae2b rdf:first Naa40a14bc1c64f69986adbc84c162f9b
127 rdf:rest N047ca003f52d4626aad01a1831fe90d7
128 Ne89ddb2a20be48fea7f0865782076770 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
129 schema:familyName Li
130 schema:givenName Guodong
131 rdf:type schema:Person
132 Ned93324152f24f9eb514859c2014eaae schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
133 schema:familyName Wang
134 schema:givenName Jialei
135 rdf:type schema:Person
136 Nf2e50e9b33d9487eb55d54c54ab6ca84 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
137 schema:familyName Zou
138 schema:givenName Liqing
139 rdf:type schema:Person
140 Nf9f8b8a2402644de989dc075202dd073 schema:name nlm_unique_id
141 schema:value 101265111
142 rdf:type schema:PropertyValue
143 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical and Health Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
147 schema:name Oncology and Carcinogenesis
148 rdf:type schema:DefinedTerm
149 sg:journal.1036451 schema:issn 1748-717X
150 schema:name Radiation Oncology
151 rdf:type schema:Periodical
152 sg:pub.10.1038/bjc.2017.395 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092730269
153 https://doi.org/10.1038/bjc.2017.395
154 rdf:type schema:CreativeWork
155 sg:pub.10.1038/srep07268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047997157
156 https://doi.org/10.1038/srep07268
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1001/jama.2016.9839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003526472
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1016/j.ijrobp.2013.11.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019077778
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1016/j.ijrobp.2014.12.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008009645
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1016/j.jtho.2017.12.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099711099
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/j.prro.2016.05.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038999889
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/j.radonc.2014.12.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043860460
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.semcdb.2016.09.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016585125
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/s0140-6736(17)30123-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1074187710
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/s1470-2045(17)30339-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1085964284
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1056/nejmct0806951 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050338991
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1056/nejmoa1006448 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029333869
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1056/nejmoa1214886 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046181766
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1056/nejmoa1408440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005474865
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1080/02841860802662722 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040375196
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1093/annonc/mds124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035605294
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1093/annonc/mdt572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016737978
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1093/annonc/mdw305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079320625
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1093/annonc/mdy121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103369506
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1093/annonc/mdy405 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106933161
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1097/jto.0000000000000648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029331288
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1097/jto.0b013e3182745948 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047119041
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1158/1535-7163.mct-12-0868 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007331796
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1200/jco.2007.15.3312 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040085264
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1200/jco.2014.59.0539 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016158843
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1200/jco.2015.62.0138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042043060
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1200/jco.2016.71.5904 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085191926
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1200/jco.2017.77.5841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104022577
211 rdf:type schema:CreativeWork
212 https://doi.org/10.3111/13696998.2014.1003644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027632484
213 rdf:type schema:CreativeWork
214 https://doi.org/10.3322/caac.21492 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106916204
215 rdf:type schema:CreativeWork
216 https://doi.org/10.3389/fonc.2018.00154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103883556
217 rdf:type schema:CreativeWork
218 https://doi.org/10.7150/jca.24950 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103988345
219 rdf:type schema:CreativeWork
220 https://www.grid.ac/institutes/grid.11841.3d schema:alternateName Shanghai Medical College of Fudan University
221 schema:name Department of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China
222 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
223 Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China
224 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
225 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China
226 rdf:type schema:Organization
227 https://www.grid.ac/institutes/grid.414906.e schema:alternateName First Affiliated Hospital of Wenzhou Medical University
228 schema:name Radiotherapy and Chemotherapy Department, the 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
229 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...